At a glance
ClinicalIndex Comparison RecordN/ACompleted· 717 enrolled
Drug / intervention
Administration of rosiglitazone/metformindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of Avandamet® Administered in Korean Diabetic Patients According to the Prescribing Information
In Brief
An observational study evaluating Administration of rosiglitazone/metformin for Diabetes Mellitus, Type 2. Completed, enrolled 717 participants.
Detailed Summary
An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of rosiglitazone/metformin administered in Korean Diabetic patients according to the prescribing information
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2004
Primary CompletionJan 2010
First PostedFeb 2011
TodayJul 2026
First PostedFeb 11, 2011
Enrollment StartJun 1, 2004
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 15.4 years ago
Interventions
Administration of rosiglitazone/metformindrug
Subjects who are administered rosiglitazone/metformin at least once